Producer
Aurobindo Pharma Limited
Indian generic pharmaceutical company (NSE: AUROPHARMA; HQ Hyderabad, Telangana; ~$3.8B revenue); one of the world's largest generic API and finished dose manufacturers. Aurobindo holds INCB quota approvals for buprenorphine API manufacture in India and exports to regulated markets (US, EU). Aurobindo's controlled substance API operations leverage India's generic pharmaceutical industrial base to serve the post-patent-cliff buprenorphine/naloxone generic market. The company's API and formulation business spans more than 150 drug categories; buprenorphine is produced within its active pharmaceutical ingredients division alongside other Schedule II controlled substances (methadone, tramadol, fentanyl intermediates). Indian buprenorphine API production for export is constrained by INCB country-level quota allocations that limit the aggregate quantity India is authorized to manufacture annually. Aurobindo also produces buprenorphine/naloxone finished dose sublingual films and tablets at its US FDA-approved facilities, sourcing API from its own manufacturing or from other qualified suppliers.
4
Inputs supplied
3
Goods downstream
3
Facilities
0
Stories
What they make
4 inputs Aurobindo Pharma Limited supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
pharmaceutical
Azithromycin API →
pharmaceutical
Fluoroquinolone APIs (ciprofloxacin HCl, ofloxacin, moxifloxacin HCl) →
pharmaceutical
Buprenorphine API →
pharmaceutical
Penicillin G (Pen G) →
Where it shows up
Goods downstream
Essential goods that depend on something Aurobindo Pharma Limited makes — pick one to see the full supply chain.
Where they make it
3 facilities
Aurobindo / Lyfius Kakinada Facility →
INKakinada, Andhra Pradesh · fermentation_and_api
Greenfield facility under India's PLI (Production Linked Incentive) scheme targeting 15,000 MT/year penicillin G capacity. Aims to reduce India's dependence on Chinese Pen G.
Aurobindo Pharma — Unit VI API Plant (Hyderabad) →
INTelangana · manufacturing
Aurobindo Pharma API manufacturing unit in Hyderabad, Telangana with USFDA approval for controlled substance APIs including buprenorphine under India's INCB manufacturing quota. Produces buprenorphine API for export to US and EU generic pharmaceutical manufacturers. India's annual INCB quota for buprenorphine is allocated across approved manufacturers. Source: https://www.aurobindo.com/manufacturing/api-manufacturing.htm
Aurobindo Unit XII (Sterile Ophthalmic) →
INTelangana · sterile_manufacturing
Dedicated sterile ophthalmic manufacturing unit; FDA-approved; produces fluoroquinolone and other ophthalmic FDF
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Antibiotic APIs (Penicillins + Cephalosporins + Fluoroquinolones)
30%Controlled Substance APIs (Opioid Addiction Treatment)
15%Generic Formulations (US + EU + Emerging Markets)
55%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Aurobindo's Hyderabad pharmaceutical manufacturing cluster serves two healthcare crises simultaneously from the same Indian API/formulation base: (1) Global antibiotic supply — Aurobindo makes fluoroquinolones (ciprofloxacin, moxifloxacin), azithromycin, cephalosporins, and penicillin-class antibiotics for treating bacterial infections worldwide; the same antibiotics used in Indian hospitals, US pharmacies, and African health clinics; (2) US opioid addiction crisis response — Aurobindo manufactures buprenorphine API (under INCB controlled substance quota) and finished buprenorphine/naloxone sublingual products (generic Suboxone) for opioid use disorder medication-assisted treatment in the United States. The 70,000 Americans who died of opioid overdoses annually (2020-2022 peak) represent the demand driver for Aurobindo's buprenorphine business. The same Telangana pharmaceutical company: making antibiotics for bacterial disease AND making the drug that keeps opioid-addicted patients alive and reduces overdose deaths. Both pharmaceutical categories address mass mortality events; both supply chains run through the same Hyderabad-area GMP facilities under the same Indian regulatory oversight.
Aurobindo Pharma Limited ↗Origin2023
Aurobindo Pharma was founded in 1986 in Hyderabad by P.V. Ramaprasad Reddy and K. Nityananda Reddy — starting with the manufacturing of semi-synthetic penicillin API (ampicillin) from Chinese-sourced 6-APA. The founding story reflects the model of Indian pharmaceutical API entrepreneurship: identify a high-demand pharmaceutical molecule with an expiring patent or weak patent protection in India, build a GMP-compliant manufacturing capability, secure US FDA Drug Master File (DMF) registration, and supply global generic drug manufacturers. Aurobindo expanded from penicillin to cephalosporins, then to fluoroquinolones, then to azithromycin, then to controlled substances — each expansion following a similar pattern of building from Indian manufacturing cost advantages and regulatory approvals. The acquisition of Actavis's Western European commercial operations in 2014 for approximately USD 300 million was a strategic pivot from pure API/bulk manufacturer to having direct branded generic presence in EU markets. A Hyderabad penicillin API company became one of the world's largest generic pharmaceutical companies in 30 years — exactly the trajectory Indian pharmaceutical policy of the 1970s-1980s was designed to create.
Aurobindo Pharma Limited ↗